Agios Pharmaceuticals (NASDAQ:AGIO) Stock Rating Upgraded by BidaskClub

BidaskClub upgraded shares of Agios Pharmaceuticals (NASDAQ:AGIO) from a sell rating to a hold rating in a research note published on Wednesday morning, BidAskClub reports.

Several other research analysts have also weighed in on AGIO. Cowen reiterated a buy rating on shares of Agios Pharmaceuticals in a report on Friday, May 31st. Goldman Sachs Group reiterated a neutral rating and set a $55.00 price objective on shares of Agios Pharmaceuticals in a report on Thursday, May 23rd. ValuEngine lowered shares of Agios Pharmaceuticals from a buy rating to a hold rating in a report on Thursday, April 18th. Royal Bank of Canada set a $89.00 price objective on shares of Agios Pharmaceuticals and gave the stock a buy rating in a report on Friday, August 2nd. Finally, Piper Jaffray Companies cut their price objective on shares of Agios Pharmaceuticals from $100.00 to $85.00 and set an overweight rating on the stock in a report on Friday, May 3rd. Seven investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company currently has a consensus rating of Hold and an average target price of $75.00.

Shares of AGIO stock opened at $42.40 on Wednesday. The firm has a market cap of $2.49 billion, a P/E ratio of -7.03 and a beta of 2.19. Agios Pharmaceuticals has a 1-year low of $38.62 and a 1-year high of $85.00. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.96 and a quick ratio of 5.91. The firm’s 50-day simple moving average is $45.28 and its 200-day simple moving average is $53.67.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.87) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.70) by ($0.17). The company had revenue of $26.22 million for the quarter, compared to analysts’ expectations of $27.05 million. Agios Pharmaceuticals had a negative return on equity of 59.89% and a negative net margin of 383.05%. The company’s revenue was down 35.1% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.19) earnings per share. Analysts expect that Agios Pharmaceuticals will post -7.25 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. NumerixS Investment Technologies Inc purchased a new position in Agios Pharmaceuticals in the second quarter valued at approximately $35,000. US Bancorp DE raised its holdings in Agios Pharmaceuticals by 82.6% in the second quarter. US Bancorp DE now owns 1,010 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 457 shares during the period. ETF Managers Group LLC raised its holdings in Agios Pharmaceuticals by 63.0% in the second quarter. ETF Managers Group LLC now owns 2,851 shares of the biopharmaceutical company’s stock valued at $142,000 after buying an additional 1,102 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Agios Pharmaceuticals by 27.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,666 shares of the biopharmaceutical company’s stock valued at $183,000 after buying an additional 779 shares during the period. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC raised its holdings in Agios Pharmaceuticals by 481.6% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 3,280 shares of the biopharmaceutical company’s stock valued at $221,000 after buying an additional 2,716 shares during the period.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.

See Also: What are popular green investing opportunities?

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.